A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study is to assess the relative bioavailability and bioequivalence of 2 strengths of the FDC tablet product SYR-322-4833 BL compared to the individual alogliptin and pioglitazone tablets in healthy Russian participants.
Epistemonikos ID: 614999a2993772949660f5c67fae897deeb1d1a3
First added on: May 21, 2024